China Resources Sanjiu Medical & Pharmaceutical (SHE:000999) recorded a 7.9% decline in attributable profit for the first half of 2026 to 1.67 billion yuan from 1.82 billion yuan a year prior.
Basic EPS fell to 1 yuan from 1.09 yuan in the corresponding period of the previous fiscal year, according to a Tuesday filing by parent China Resources Pharmaceutical (HKG:3320).
The pharmaceutical company's operating revenue increased 1.4% to 15 billion yuan from 14.8 billion yuan previously.